These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32338233)

  • 21. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.
    Reimherr FW; Williams ED; Strong RE; Mestas R; Soni P; Marchant BK
    J Clin Psychiatry; 2007 Jan; 68(1):93-101. PubMed ID: 17284136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of subtype and psychiatric comorbidities on methylphenidate treatment in adults with attention-deficit hyperactivity disorder].
    Sobanski E; Alm B; Krumm B
    Nervenarzt; 2007 Mar; 78(3):328-30, 333-37. PubMed ID: 16544121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II--broader executive and non-executive domains.
    Rhodes SM; Coghill DR; Matthews K
    J Child Psychol Psychiatry; 2006 Nov; 47(11):1184-94. PubMed ID: 17076758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Attention-Deficit/Hyperactivity Disorder and Methylphenidate Treatment on the Adult Auditory Temporal Order Judgment Threshold.
    Fostick L
    J Speech Lang Hear Res; 2017 Jul; 60(7):2124-2128. PubMed ID: 28672285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life of methylphenidate treatment-responsive adolescents with attention-deficit/hyperactivity disorder.
    Yang PC; Lung FW; Chiou SS; Yen CF; Fuh JL
    Kaohsiung J Med Sci; 2012 May; 28(5):279-84. PubMed ID: 22531308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immediate effects of methylphenidate on cognitive attention skills of children with attention-deficit-hyperactivity disorder.
    Hood J; Baird G; Rankin PM; Isaacs E
    Dev Med Child Neurol; 2005 Jun; 47(6):408-14. PubMed ID: 15934489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurocognitive assessment of children with neurodevelopmental disorders: Preliminary findings.
    Kawabe K; Horiuchi F; Kondo S; Matsumoto M; Seo K; Oka Y; Ueno SI
    Pediatr Int; 2018 Sep; 60(9):820-827. PubMed ID: 30019794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
    Philipsen A; Jans T; Graf E; Matthies S; Borel P; Colla M; Gentschow L; Langner D; Jacob C; Groß-Lesch S; Sobanski E; Alm B; Schumacher-Stien M; Roesler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Heinrich V; Huss M; Kornmann C; Bürger A; Perlov E; Ihorst G; Schlander M; Berger M; Tebartz van Elst L;
    JAMA Psychiatry; 2015 Dec; 72(12):1199-210. PubMed ID: 26536057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel multidomain computerized cognitive assessment for attention-deficit hyperactivity disorder: evidence for widespread and circumscribed cognitive deficits.
    Leitner Y; Doniger GM; Barak R; Simon ES; Hausdorff JM
    J Child Neurol; 2007 Mar; 22(3):264-76. PubMed ID: 17621495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of methylphenidate on spatial attention asymmetry in adolescents with attention deficit hyperactivity disorder (ADHD): preliminary findings.
    Silk TJ; Newman DP; Eramudugolla R; Vance A; Bellgrove MA
    Neuropsychologia; 2014 Apr; 56():178-83. PubMed ID: 24486422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
    Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
    JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive heterogeneity in adult attention deficit/hyperactivity disorder: A systematic analysis of neuropsychological measurements.
    Mostert JC; Onnink AMH; Klein M; Dammers J; Harneit A; Schulten T; van Hulzen KJE; Kan CC; Slaats-Willemse D; Buitelaar JK; Franke B; Hoogman M
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2062-2074. PubMed ID: 26336867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
    J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.
    Pan PY; Fu AT; Yeh CB
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):682-689. PubMed ID: 30148656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.